Cortice Biosciences Announces Enrollment Of A Phase 2 Trial Evaluating TPI 287 Plus Avastin® For Treatment Of Glioblastoma Previously Treated With Anti-Angiogenic Therapy
3/20/2014 8:53:03 AM
NEW YORK, March 20, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and efficacy of the Company's lead drug candidate, TPI 287, in combination with standard-of-care Avastin® (bevacizumab) for treatment of patients with recurrent glioblastoma (GBM) that has progressed following Avastin treatment alone (clinicaltrials.gov/NCT02047214). TPI 287 is an abeotaxane, a novel taxoid derivative that works similarly to taxane chemotherapeutics, such as Taxol®, Abraxane®, and Taxotere®, but with the distinct advantages of being able to readily cross the blood-brain barrier and evade common drug resistance mechanisms.
Help employers find you! Check out all the jobs and post your resume.
comments powered by